Masahiro Tohkin Selected Research

Stevens-Johnson Syndrome (Lyell's Syndrome)

2/2018	Allopurinol suppresses expression of the regulatory T-cell migration factors TARC/CCL17 and MDC/CCL22 in HaCaT keratinocytes via restriction of nuclear factor-κB activation.
11/2013	Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects.
1/2012	Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese.
12/2010	HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients.
11/2008	HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masahiro Tohkin Research Topics

Disease

6	Neoplasms (Cancer) 11/2023 - 01/2009
5	Stevens-Johnson Syndrome (Lyell's Syndrome) 02/2018 - 11/2008
4	Multiple Myeloma 12/2021 - 10/2019
2	Acute Kidney Injury (Acute Renal Failure) 01/2024 - 11/2021
2	Chronic Renal Insufficiency 01/2024 - 01/2021
2	Type 2 Diabetes Mellitus (MODY) 01/2020 - 05/2006
2	Weight Gain 01/2019 - 05/2006
1	Hyponatremia 11/2023
1	Chemical and Drug Induced Liver Injury 05/2023
1	Hemorrhage 01/2023
1	Atrial Fibrillation 01/2023
1	Stroke (Strokes) 01/2023
1	Embolism (Embolus) 01/2023
1	Pneumonia (Pneumonitis) 12/2021
1	Melanoma (Melanoma, Malignant) 11/2021
1	Fibrosarcoma 11/2021
1	Dysuria 01/2021
1	Schizophrenia (Dementia Praecox) 01/2021
1	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2021
1	Cicatrix (Scar) 01/2021
1	Tumor Lysis Syndrome 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2019
1	Hepatitis B 01/2018
1	Infections 01/2018
1	Skin Diseases (Skin Disease) 01/2018
1	Heart Failure 01/2017
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2017
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2017
1	Lactic Acidosis 06/2015
1	Hypertrophy 01/2015
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2012
1	Stomach Neoplasms (Stomach Cancer) 01/2012
1	Breast Neoplasms (Breast Cancer) 01/2012
1	Hand-Foot Syndrome 01/2012
1	Hypoxia (Hypoxemia) 01/2011

Drug/Important Bio-Agent (IBA)

5	Bortezomib (Velcade)FDA Link 11/2023 - 01/2018
5	HLA-B Antigens (HLA-B)IBA 05/2023 - 11/2008
5	Biomarkers (Surrogate Marker)IBA 12/2021 - 01/2010
3	SodiumIBA 11/2023 - 01/2018
3	Allopurinol (Remid)FDA LinkGeneric 01/2021 - 11/2008
2	Antineoplastic Agents (Antineoplastics)IBA 11/2023 - 01/2018
2	Carbamazepine (Tegretol)FDA LinkGeneric 01/2021 - 12/2010
2	Phenytoin (Dilantin)FDA LinkGeneric 01/2021 - 11/2013
2	Lenalidomide (CC 5013)FDA Link 04/2020 - 01/2020
2	SymportersIBA 01/2020 - 01/2018
2	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2018
2	XenobioticsIBA 01/2015 - 01/2011
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2024
1	Immune Checkpoint InhibitorsIBA 11/2023
1	pembrolizumabIBA 11/2023
1	Cisplatin (Platino)FDA LinkGeneric 11/2023
1	Warfarin (Coumadin)FDA LinkGeneric 01/2023
1	AnticoagulantsIBA 01/2023
1	HLA-DRB1 Chains (HLA DRB1)IBA 12/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021
1	Phosphotransferases (Kinase)IBA 11/2021
1	MitogensIBA 11/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 11/2021
1	asenapine FDA Link 01/2021
1	insulin receptor-related receptor (IRR)IBA 01/2021
1	Tadalafil (Cialis)FDA Link 01/2021
1	Dexamethasone (Maxidex)FDA LinkGeneric 04/2020
1	Thalidomide (Thalomid)FDA Link 01/2020
1	Proteasome InhibitorsIBA 10/2019
1	Diethylhexyl Phthalate (DEHP)IBA 01/2019
1	p38 Mitogen-Activated Protein KinasesIBA 02/2018
1	Imatinib Mesylate (Gleevec)FDA Link 01/2018
1	Azacitidine (5 Azacytidine)FDA Link 01/2018
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2018
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018
1	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2018
1	taxaneIBA 01/2018
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018
1	Drug CombinationsIBA 01/2018
1	Rituximab (Mabthera)FDA Link 01/2018
1	Trastuzumab (Herceptin)FDA Link 01/2018
1	fludarabineIBA 01/2018
1	Everolimus FDA Link 01/2018
1	Antihypertensive Agents (Antihypertensives)IBA 01/2017
1	DiureticsIBA 01/2017
1	Lactic Acid (Lactate)FDA LinkGeneric 06/2015
1	Metformin (Glucophage)FDA LinkGeneric 06/2015
1	Phenobarbital (Luminal)FDA Link 11/2013
1	Zonisamide (Zonegran)FDA LinkGeneric 11/2013
1	Anticonvulsants (Antiepileptic Drugs)IBA 11/2013
1	Tumor Biomarkers (Tumor Markers)IBA 01/2012
1	Fluorouracil (Carac)FDA LinkGeneric 01/2012
1	Carcinoembryonic AntigenIBA 01/2012
1	CarbohydratesIBA 01/2012
1	AntigensIBA 01/2012
1	Capecitabine (Xeloda)FDA Link 01/2012
1	ProdrugsIBA 01/2012
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 01/2011
1	ElementsIBA 01/2011

Therapy/Procedure

7	Therapeutics 11/2021 - 03/2005
4	Drug Therapy (Chemotherapy) 11/2021 - 01/2010
1	Kampo Medicine (Kampo) 05/2023
1	Antineoplastic Combined Chemotherapy Protocols 01/2018
1	Time-to-Treatment 01/2012